Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: GSK deal strengthens its infectious disease pipeline; an analysis of the first drugs subject to US Medicare price negotiations; Roche partnering head talks about strategy; promising early Alzheimer’s results for Biogen’s tau drug; and what India needs to become a world-class innovation hub.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 7April 2023, including: GSK plc deal strengthens its infectious disease pipeline; an analysis of the first drugs subject to US Medicare price negotiations; Roche Holding AG partnering head talks about strategy; promising early Alzheimer’s results for Biogen, Inc.’s tau drug; and what India needs to become a world-class innovation hub.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "GSK Boosts Its Infectious Disease Portfolio With Brexafemme License" - Scrip, 30 Mar, 2023.)
(Also see "First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands" - Scrip, 30 Mar, 2023.)
(Also see "Roche Continues To Cast Its Collaborations Net Wide" - Scrip, 30 Mar, 2023.)
(Also see "Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?" - Scrip, 3 Apr, 2023.)
(Also see "Whiteboarding Ideas From Novartis, Novo To Address India’s Elephants In The Room, ‘On Streets’" - Scrip, 31 Mar, 2023.)